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We demonstrated that unmodified and modified (phosphorothioate) oligonucleotides prevent cDNA synthesis by AMV or HIV reverse transcrip- 
tases. Antisense oligonucleotide/RNA hybrids specifically arrest primer extension. The blockage involves the degradation of the RNA fragment 
bound to the antisense oligonucleotide by the reverse transcriptase-associated RNase H activity. However, the phosphorothioate oligomer inhibited 
polymerization by binding to the AMV RT rather than to the template RNA, whereas there was no competitive binding of the phosphorothioate 
oligomer on the HIV RT during reverse transcription. 
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1. INTRODUCTION 
Antisense RNA or antisense oligodeoxyribonucleo- 
tides within cells targeted toward the RNA transcript of 
a specific gene can inhibit the expression or promote the 
degradation of the transcript, resulting in suppression 
of the function coded for by the gene. The addition of 
chemically modified antisense oligomers to culture me- 
dium and their uptake by cells has been used to inhibit 
the expression of specific target genes [ll4]. These com- 
pounds have been used as antisense inhibitors of gene 
expression in various culture systems and are consid- 
ered to be potential therapeutic agents [5,6]. 
Antisense oligonucleotides complementary to viral 
RNA inhibit viral replication in cells cultured with Rous 
sarcoma virus [7], human irnmunodeficiency virus [8- 
lo], vesicular stomatitis virus [11,12], herpes simplex 
virus [11,14], and influenza virus [14,15]. 
However, the mechanism by which the antisense ol- 
igonucleotide inhibited retroviral protein synthesis, 
syncytia formation, and reverse transcriptase activity 
has not been fully elucidated. Recently, Toulmt et al. 
have reported that unmodified oligonucleotides indeed 
arrested cDNA synthesis by AMV and MMLV RTs 
which have RNase H activity, but that &-oligonucleo- 
tide analogues did not [ 16,171. 
We present here a detailed analysis of the effect of 
unmodified and modified (phosphorothioate) oligode- 
oxyribonucleotides [I 81 on cDNA synthesis by AMV 
and HIV [19] RTs. The phosphorothioate oligonucleo- 
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tides that are nuclease-resistant analogues of oligodeox- 
yribonucleotides can be used to prevent reverse tran- 
scription. 
2. MATERIALS AND METHODS 
2.1. Oligonucleotides 
The unmodified oligonucleotide derivatives S-d[TTGTGTCAAA- 
AGCAAGT] [17 cap (n)], S-d[CACCAACTTCTTCCACA] [ 17 sc (n)] 
and Y-d[TGCCCAGGGCCTCAC] [15sc (n)], and modified (phos- 
phorothioate) oligodeoxyribonucleotide derivatives 5’-d[TsTsGsTs- 
GsTsCsAsAsAsAsGsCsAsAsGsT] [17 cap (s)] and S-d[CsAsCsCs- 
AsAsCsTsTsCsTsTsCsCsAsCsA] [17 SC (s)] were synthesized on a 
Biosearch synthesizer. The oligonucleotide derivatives were purified 
by reverse-phase HPLC on an oligo-DNA column. Purified oligomers 
were evaluated by resolving 32P-labeled by electrophoresis samples on 
20% polyacrylamidel7 M urea gels. 
2.2. Enzymes and mRNAs 
Escherichia coli RNase H and RNasin were from Promega. T4 
polynucleotide kinase was purchased from Toyo Boseki. AMV with 
RNase H as well as rabbit globin mRNA were purchased from Gibcol 
BRL and was used without treatment. HIV RT with RNase H was 
from Seikagaku Kogyo. A fragment, about 150 nucleotides long, was 
obtained by directed cleavage of rabbit /?-globin mRNA by E. coii 
RNase H. /I-globin mRNA (0.5 pg) was incubated with E. coli RNase 
H (10 U) in the presence of an oligonucleotide 15 (100 pmol) comple- 
mentary to nucleotides 147-161 of thep-globin mRNA. The reaction 
mixture was incubated for 2 h at 37°C in 20 ~1 of a 20 mM Tris-HCI 
(pH 7.5) buffer containing 10 mM MgCl,, 100 mM KC1 and 0.1 mM 
dithiothreitol. After the reaction, the fragment, which was about a 
150-nucleotide mRNA was phenol-extracted, ethanol-precipitated 
and dissolved in 25 ~1 of sterile water. 
2.3. cDNA synthesis 
Globin RNA (50 ng, containing 0.3 pmol of intact the /I-globin), 
primer (50 pmol), and the desired amount of antisense oligonucleo- 
tides were preincubated for 30 min at 39°C. After adding 1 ~1 of 
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10 x RT buffer (1 M Tris-HCl, pH 8.3,720 mM KCI, 100 mM MgCl,, 
100 mM dithiothreitol) containing 8 U of RNasin, 2 pmol of [a- 
‘*P]dCTP (3000 CYmmol; Ci = 37GBq; NEN), 5 nmol of the three 
dNTPs and 2.5 nmol of dCTP, the volume of the mixture was adjusted 
to 10 pl with sterile water. AMV RT (l-10 U, i.e. 0.13-1.3 pmol) was 
then added. The reaction with HIV RT was allowed to proceed with 
1 U, incubated for 1 h at 39°C. The cDNA was chloroform-extracted 
according to standard procedures, and loaded on a 10% PAGE. The 
results obtained for cDNA synthesis were corrected for the number 
of labels incorporated into each fragment. 
a 
3. RESULTS AND DISCUSSION b 
Reverse transcription of rabbit j?-globin mRNA by 
AMV RT was primed with 17 SC, complementary to 
oligonucleotide 113-129 (Fig. l), giving rise to the pre- 
dicted cDNA fragment of about 130 nucleotides (Fig. 
2a). In contrast, when the polymerization was per- 
formed in the presence of 17 cap (n) (0.05-2 PM), an 
oligonucleotide targeted to the cap region of the 
mRNA, a shortened DNA fragment was synthesized, at 
the expense of the full-length product. The size of the 
cDNA fragment corresponded to the distance between 
the primer and binding site of the antisense oligonucle- 
otides (Fig. 1). Therefore, the hybridization of this an- 
tisense oligonucleotide with the complementary se- 
quence of the B-globin mRNA prevents transcription of 
this region. The inhibitory efficiency was dependent on 
the 17 cap (n) concentration. At concentrations as low 
as 1.0 ,uM, 17 cap (n), 98% inhibition of reverse tran- 
scription was observed. This resulted from competition 








Fig. 2. Effect of the unmodified and mod&d antisense. oligonucleo- 
tides on DNA synthesis. (a) Reverse transcription proceeded as indi- 
cated using 10 U of AMV RT primed by 5 PM oligomer 17 sc (n) 
without (0) or with various amounts @M) of oligomer 17 cap (n). (b) 
cDNA analysis of the 17 cap (s) used in place of the 17 cap (n) in a. 
First lanes on left (M) in a and b correspond to DNA size markers. 
cDNA can not be completely blocked by the decrease 
of the binding of the phosphorothioate oligomer to 
mRNA. This process was essentially sequence inde- 
pendent and was the result of the preferential binding 
of the modified oligomers to the RT enzyme compared 
with unmodified oligomers. 
Next, we examined the cDNA synthesis by AMV 
reverse transcriptase using the 17 cap (s), phospho- 
rothioate oligomer instead of 17 cap (n). Fig. 2b shows 
that 17 cap (s) reduced the synthesis of the 110 nucleo- 
tide transcript; at concentrations of 1, 2, and 4 ,um, the 
percentages of inhibition were 55%, 74% and 82%, re- 
spectively. However, these values are lower than that of 
the unmodified oligonucleotide at 1 PM. This suggested 
that part of the phosphorothioate oligomer binds to the 
RT enzyme. As a result, the synthesis of full-length 
To characterize the inhibitory process of the phos- 
phorothioate oligomers, we incubated antisense oligom- 
ers, 17 cap (n) or 17 cap (s) (2 PM) and the 17 sc (n) 
primer (5 PM) with AMV RT at concentrations of 1 or 
10 units under the same conditions as described above. 
Smaller amounts of AMV RT were used because the 
polymerase activity aborts synthesis. The synthesis of 
cDNA with 17 cap (n) was inhibited by 1 unit of AMV 
RT. However, cDNA synthesis was significantly de- 
creased when the modified oligomer, 17 cap (s) was used 
a 
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Fig. 1. Inhibition of reverse transcription by complementary oligonucleotides. The full length cDNA products derived from 17 SC (n) or 15 SC (n) 
(a) could be blocked by the antisense oligomers, 17 cap (n or s) and 17 SC (n or s) bound to a template sequence (b) or adjacent (c) to the 
primer-binding site. 
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Fig. 3. The interaction between the antisense oligomers and AMV RT 
on the reverse transcript. Analysis of cDNA fragments ynthesized by 
1 U (left) or 10 U (right) of AMV RT. The reaction primed by al7 
[17 se (n) (5 PM)] complementary to the 113-129 oligonucleotide 
without (-) or with 2 PM antisense oligonucleotides, 17 cap (n) and 
17 cap (s). DNA size markers were run in lane M. 
(Fig. 3). It should be noted that the cDNA could not be 
synthesized by a fall of ability of the polymerization due 
to the competitive binding of phosphorothioate oligom- 
ers on the RT enzyme. On the other hand, when the 
AMV RT concentration was 10 units, the short 123 
nucleotide transcript was detected in all cases (Fig. 3). 
This suggests a relationship between the RT enzyme 
and phosphorothioate oligomer and its inhibitory effi- 
ciency [9,20]. It should be pointed out that the antisense 
phosphorothioate oligomer did not compete directly 
with the mRNA as the RT enzyme. 
To further characterize the inhibitory process of the 
phosphorothioate oligomers, we examined how to pre- 
vent cDNA elongation by HIV RT instead of AMV RT 
under the same conditions as described above. Fig. 4 
shows that the antisense oligomers 17 cap (n) and 17 cap 
(s) induced the characteristic shortened cDNA frag- 
ments when the reaction proceeded with HIV RT. The 
ANTISENSE 17cap(n) 17cap(s) 
M - 0.5 1 2 0.5 1 2 (PM) 
Fig. 4. Effect of antisense oligonucleotides on cDNA synthesis using 
HIV RT. Reverse transcription proceeded as indicated using 1 U of 
HIV RT primed by a 17mer [17 SC (n) (5 PM)] complementary to the 
113-129 oligonucleotide without (-) or with various amounts @M) 
of antisense oligonucleotides, 17 cap (n) (left) and 17 cap (s) (right). 
DNA markers were run in lane M. 
PRUSR lssc(rl) 1130 - 1441 
ANnsENsE - 179m 17sc(S) 
M 0.5 2 10 05 2 IO W4 
Fig. 5. Effect of the relative location of antisense and primer-binding 
sites. Analysis of cDNA fragments ynthesized by 1 U of AMV RT. 
The reaction primed by a 15 complementary to the 130-144 oligonu- 
cleotide (5 PM) without (-) or with the antisense oligonucleotides, 17 
SC (n) or 17 SC (s) at the concentrations QM) indicated above the lanes. 
DNA size markers were run in lane M. 
17 cap (s) at a concentration as low as 1 .O ,uM resulted 
in a shortened DNA fragment at the expense of the 
full-length product. This indicated that the phospho- 
rothioate oligonucleotide inhibited the production of 
cDNA by being a retroviral polymerase by bound to the 
RNA downstream from the primer. However, the inhib- 
itory efficiency of phosphorothioate oligonucleotide is 
influenced by its relationship with RT. 
We speculated that an oligomer adjacent to the 
primer (see Fig. 1) could function by a different mecha- 
nism: the primer-antisense tandem may be viewed as a 
single complementary sequence by the priming RT mol- 
ecule. To test this mechanism, we synthesized the un- 
modified [17 SC (n)] and the modified [I7 SC (s)] oligonu- 
cleotides complementary to nucleotides 113-129 of rab- 
bit p-globin mRNA and unmodified 15,15 SC (n) com- 
plementary to nucleotides 130-144. Fig. 5 shows that 17 
SC (n) or 17s~ (s) reduced the synthesis of the 144 nucle- 
otide long transcript; complete inhibition was achieved 
at c 2 ,uM. This suggests that the oligomer complemen- 
tary to a site immediately adjacent o the primer binding 
site could then act as a primer which would be length- 
ened by polymerase. The inhibition involved degrada- 
tion of the template by RNase H. However, the effi- 
ciency of an oligomer adjacent o the primer binding site 
was lower than that of an antisense oligomer bound to 
the 5’-end of mRNA. Furthermore, increased concen- 
trations of the 17 SC (s) phosphorothioate oligomer in 
the reverse transcription mixture containing AMV RT 
(1 unit), led to the disappearance of the cDNA tran- 
script. This result also suggested that the antisense 
phosphorothioate oligonucleotide inhibited polymeri- 
zation by binding to the enzyme RT rather than to the 
template RNA. 
It is notable that the antisense phosphorothioate ol- 
igonucleotide participates through a mechanisms of in- 
teraction different from those of the RT enzymes, in 
adherence and structural differences. Furthermore, the 
efficiency of an antisense oligomer bound to the 5’ end 
163 
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of mRNA is higher than that of an oligomer adjacent 
to the primer. Therefore, the antisense oligonucleotides 
can be used with intact cells, and they prevent the devel- 
opment of retrovirus in culture. 
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